ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2015
Prevention of hepatitis B virus infection: from the past to the future.
Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection.Nature communications · 2021Trial
- Review
- Temporal trend analysis of acute hepatitis B virus infection in China, 1990-2019.Epidemiology and infection · 2024Article
- OVA-PEG-R848 nanocapsules stimulate neonatal conventional and plasmacytoid dendritic cells.Frontiers in pediatrics · 2022Article
- Principles in Immunology for the Design and Development of Vaccines.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Hepatitis B Virus Infection in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.Journal of personalized medicine · 2021Review
- Hepatitis B virus S gene therapy with 10-23 DNAzyme delivered by chitosan-RSC advances · 2019Article
- A rapid and sensitive recombinase aided amplification assay to detect hepatitis B virus without DNA extraction.BMC infectious diseases · 2019Article
- Promising practices for the prevention of liver cancer: a review of the literature and cancer plan activities in the National Comprehensive Cancer Control Program.Cancer causes & control : CCC · 2018Review
- Current evidence on the management of hepatitis B in pregnancy.World journal of hepatology · 2018Review
- Decreasing prevalence of Hepatitis B and absence of Hepatitis C Virus infection in the Warao indigenous population of Venezuela.PloS one · 2018Article
- Liver Illness and Psoriatic Patients.BioMed research international · 2018Review
- Tumour virus vaccines: hepatitis B virus and human papillomavirus.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2017Review
- Quantifying perinatal transmission of Hepatitis B viral quasispecies by tag linkage deep sequencing.Scientific reports · 2017Article
- To screen or not to screen? Celiac antibodies in liver diseases.World journal of gastroenterology · 2017Review
- A school-based intervention of screening a movie to increase hepatitis B vaccination levels among students in Uttar Pradesh, India: impact on knowledge, awareness, attitudes and vaccination levels.Hepatology, medicine and policy · 2017Article
- Active immunization in patients transplanted for hepatitis B virus related liver diseases: A prospective study.PloS one · 2017Article
- [Research advances in necessity of antiviral therapy for chronic hepatitis B virus carriers].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2016Review
- Inhibition of HBV Replication by a Fully Humanized Neutralizing Antibody In Vivo and In Vitro.Acta naturaeArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
About 3-5 % of the world's population is chronically infected by hepatitis B virus (HBV) and is at risk of developing liver cirrhosis or hepatocellular carcinoma. The risk of dying prematurely because of chronic HBV infection is higher in younger people. The current strategies to prevent HBV infection involve immunization (active and/or passive) and antiviral chemoprophylaxis. The vaccines available for active immunization, containing hepatitis B surface antigen, are safe and confer long-term immunity in most healthy subjects. Since the vaccination is unsatisfactory in some patients, e.g., those with chronic kidney disease, human immunodeficiency virus infection, type I diabetes mellitus, and celiac disease, new strategies of vaccination are required. The neonatal, infant, and adolescent routine program vaccination in about 180 countries has greatly decreased the disease burden. Passive immunization with specific HBV immunoglobulins is recommended after single acute exposure, in infants born to infected mothers, and in HBV-infected patients undergoing liver transplantation combined with nucleoside/nucleotide analogues (chemoprophylaxis). Chemoprophylaxis is also indicated in HBV carrier candidates for immunosuppressive treatment and in patients with occult B infection undergoing immunosuppressive therapy or hematopoietic stem cell transplantation. Since HBV is not eradicable by an immune response or by antiviral drugs developed so far, the only preventive strategy remains global neonatal vaccination in all countries, firstly in HBV-endemic countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.